[Classification and treatment of torsades de pointes (TdP): a report of 11 cases]
Insights
This study analyzed 11 Torsades de Pointes (TdP) cases, finding magnesium sulfate effective for TdP with normal QT intervals but not long QT syndrome. Certain antiarrhythmics are contraindicated in long QT syndrome TdP.
Area of Science:
- Cardiology
- Clinical Medicine
- Pharmacology
Context:
- Torsades de Pointes (TdP) is a life-threatening ventricular arrhythmia.
- Patients often have underlying conditions like coronary heart disease and electrolyte imbalances.
- Previous treatment guidelines for TdP in specific patient groups are limited.
Purpose:
- To analyze clinical characteristics and treatment outcomes of Torsades de Pointes (TdP).
- To evaluate the efficacy of magnesium sulfate and other interventions in TdP management.
- To identify contraindications for antiarrhythmic drug use in TdP patients with long QT syndrome.
Summary:
- Eleven TdP cases were analyzed, divided into 9 with long QT syndrome and 2 with normal QT interval.
- Common comorbidities included coronary heart disease, atrioventricular block, and hypokalemia.
- Magnesium sulfate effectively treated TdP in 7/9 patients with normal QT intervals but was ineffective in long QT syndrome cases.
- Class Ia and III antiarrhythmics were contraindicated in TdP with long QT syndrome but permissible in TdP with normal QT interval.
Impact:
- Provides evidence-based treatment recommendations for TdP based on QT interval status.
- Highlights the differential efficacy of magnesium sulfate in TdP management.
- Informs clinical practice regarding antiarrhythmic drug selection in TdP patients.
- Contributes to understanding TdP pathophysiology and management in complex cardiac conditions.
Abstract:
A clinical analysis of 11 cases with TdP was reported. These patients were divided into two groups: 9 cases with long QT syndrome and 2 with normal QT interval. All of the patients suffered from coronary heart disease with various concomitant ailments, such as pulmonary heart disease (1 case), atrioventricular block (5 cases with complete or type II second degree AV block), hypokalemia (7 cases). In one case the TdP was caused by aminodarone administration. The principle of treatment included removing the inducing causes, treating the primary diseases and interrupting TdP. All patients who had hypokalemia were treated with potassium chloride. 7 of 9 cases showed effective response to treatment with magnesium sulfate. The patients with long QT syndrome failed to respond with MgSO4. Severe bradycardia should be treated with isoprenaline. Only one patient had pacing therapy and another received electric conversion. According to our experience, for patients of TdP with long QT syndrome class Ia and III antiarrhythmic agents were contraindicated, but those with normal QT interval can take these drugs.
More Related Videos
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
12:15Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease
Published on: February 8, 2022
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias II: Classification of Tachyarrhythmias
Dysrhythmias III: Characteristics of Dysrhythmias
Dysrhythmias V: Evaluating Dysrhythmias
Dysrhythmias VI: Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
